News

As Alzheimer's disease progresses beyond the early stages, the behavior changes and emotional impacts of the disease can be ...
Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...
Scientists challenging conventional beliefs around the genetic risk factors for Alzheimer’s have discovered a genetic link ...
A woman was told she had Alzheimer’s 13 years ago. Now she’s walking the width of the U.S. after reversing her illness - US LIFESTYLE: After getting a devastating diagnosis of Alzheimer’s — shortly ...
Austin Public Health looks at 10 years worth of mortality data by disease, gender and race in new chronic disease report.
Treatment with memantine in a small cohort of individuals with post-traumatic headache led to fewer average headache days per ...
In those nations, MAID is available to a wider universe of pained people, not just those with fewer than six months to live.
Synendos Therapeutics appoints Dr. George Garibaldi to move phase 2 clinical development of its lead drug asset SYT-510: Basel, Switzerland Wednesday, July 16, 2025, 15:45 Hrs [IS ...
Risks to BMY include potential for tariffs to raise costs of drugs manufactured outside of the U.S. Moreover, drug pricing ...
Synendos Therapeutics (“Synendos”), the clinical-stage biotechnology company developing breakthrough therapies for ...
Overview of Autologous Cell Therapy Product MarketGlobal Cell Therapy Market is valued at USD 10.1 Billion in 2025 and is ...
With clinical trials under pressure, industry leaders say it’s time for reform, digital transformation, and more patient-centric models.